

**Access to cyano-substituted pyrazolines through copper-catalyzed
cascade cyanation/cyclization of unactivated olefins**

Fei Meng, Qin Fang, Weidong Yuan, Ning Xu, Shujun Cao, Jianlin Chun, Jie Li,
Honglin Zhang* and Yingguang Zhu*

*Jiangsu Key Laboratory of Pesticide Science and Department of Chemistry, College
of Sciences, Nanjing Agricultural University, Nanjing 210095, China*

E-mail: ygzhu@njau.edu.cn; honglinzh@njau.edu.cn

Supporting Information

Table of Contents

General information.....	S2
General procedure for the domino cyanation/cyclization reaction.....	S2
Procedure for the radical trapping experiment.....	S2
Characterization data.....	S3
References.....	S14
NMR spectra.....	S15

General information. All commercially available reagents were used without further purification. Column chromatography was performed on silica gel (200-300 mesh). ^1H NMR (400 MHz) and ^{13}C NMR (100 MHz) spectra were recorded on a 400 MHz spectrometer. Chemical shifts (δ) were reported in ppm, and coupling constants (J) were given in Hertz (Hz). Data were reported as s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet. High-resolution mass spectra (HRMS) were recorded on an AB SCIEX Triple TOF 5600+ mass spectrometer. Substrates **1a–1r** and **1t** were synthesized via the allylation¹ of the corresponding aldehyde, oxidation,² and hydrazonation.³ Alkenyl hydrazone **1s** was obtained according to the literature procedure.^{4,2,3} Substrate **1u** was prepared following the reported methods.⁵ Alkenyl hydrazone **1v** was synthesized according to the literature methods.^{6,3}

General procedure for the domino cyanation/cyclization reaction (Scheme 1).

To a reaction tube equipped with a magnetic stir bar were added alkenyl hydrazone **1** (0.20 mmol), $\text{Zn}(\text{CN})_2$ (47.0 mg, 0.40 mmol), $\text{Cu}(\text{acac})_2$ (5.2 mg, 0.020 mmol), $\text{K}_2\text{S}_2\text{O}_8$ (135.2 mg, 0.50 mmol), NaHCO_3 (25.2 mg, 0.30 mmol), and DMSO (1.6 mL). The reaction mixture was vigorously stirred at room temperature until the reaction was completed as monitored by TLC analysis, diluted with water (15 mL), and extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 5:1 or 3:1) to give product **2**.


Procedure for the radical trapping experiment (Scheme 3B).

To a reaction tube equipped with a magnetic stir bar were added alkenyl hydrazone **1a** (62.9 mg, 0.20 mmol), $\text{Zn}(\text{CN})_2$ (47.0 mg, 0.40 mmol), $\text{Cu}(\text{acac})_2$ (5.2 mg, 0.020 mmol), $\text{K}_2\text{S}_2\text{O}_8$ (135.2 mg, 0.50 mmol), NaHCO_3 (25.2 mg, 0.30 mmol), TEMPO (62.5 mg, 0.40 mmol), and DMSO (1.6 mL). The reaction mixture was stirred at room temperature for 12 h, diluted with water (15 mL), and extracted with ethyl acetate (10 mL $\times$ 3). The

combined organic layers were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 10:1) to give TEMPO-trapped pyrazoline **3**.


Characterization data

2-(3-phenyl-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (**2a**)



White solid (0.20 mmol scale: 51.4 mg, 76%; 5.0 mmol scale: 1.22 g, 72%); ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, J = 8.2 Hz, 2H), 7.67 – 7.61 (m, 2H), 7.48 – 7.34 (m, 3H), 7.31 (d, J = 8.1 Hz, 2H), 4.15 – 4.02 (m, 1H), 3.36 (dd, J = 17.3, 10.9 Hz, 1H), 3.24 (dd, J = 17.0, 3.6 Hz, 1H), 3.12 (dd, J = 17.3, 9.5 Hz, 1H), 3.05 (dd, J = 17.0, 8.2 Hz, 1H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.2, 145.0, 131.1, 131.0, 129.9, 129.7, 128.7, 128.6, 126.9, 116.4, 57.5, 39.3, 24.5, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{NaO}_2\text{S}$ 362.0934, found 362.0937.


2-(3-(2-methoxyphenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (**2b**)



White solid (57.7 mg, 78%); ^1H NMR (400 MHz, CDCl_3) δ 7.85 – 7.75 (m, 3H), 7.37 (t, J = 8.0 Hz, 1H), 7.32 (d, J = 7.9 Hz, 2H), 6.95 (t, J = 7.6 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 4.06 – 3.93 (m, 1H), 3.78 (s, 3H), 3.45 (dd, J = 18.2, 10.7 Hz, 1H), 3.27 (dd,


$J = 18.3, 10.0$ Hz, 1H), 3.20 (dd, $J = 17.0, 3.0$ Hz, 1H), 3.02 (dd, $J = 16.9, 8.0$ Hz, 1H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.9, 157.3, 144.8, 132.2, 131.1, 129.6, 129.4, 128.7, 120.7, 119.0, 111.3, 57.6, 55.4, 42.6, 24.4, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{NaO}_3\text{S}$ 392.1039, found 392.1032.

2-(3-(2-chlorophenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2c)




White solid (52.4 mg, 70%); ^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, $J = 8.2$ Hz, 2H), 7.62 – 7.56 (m, 1H), 7.40 – 7.31 (m, 4H), 7.30 – 7.26 (m, 1H), 4.17 – 4.05 (m, 1H), 3.51 (dd, $J = 17.7, 10.6$ Hz, 1H), 3.30 (dd, $J = 17.7, 9.8$ Hz, 1H), 3.21 (dd, $J = 17.0, 3.6$ Hz, 1H), 3.08 (dd, $J = 17.0, 7.7$ Hz, 1H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.3, 145.1, 132.7, 131.5, 131.1, 130.6, 130.5, 129.8, 129.4, 128.7, 127.0, 116.2, 57.9, 42.2, 24.3, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{ClN}_3\text{NaO}_2\text{S}$ 396.0544, found 396.0551.

2-(3-(3-methoxyphenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2d)




White solid (49.6 mg, 67%); ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, $J = 7.9$ Hz, 2H), 7.34 – 7.27 (m, 3H), 7.22 (s, 1H), 7.15 (d, $J = 7.8$ Hz, 1H), 6.97 (dd, $J = 8.3, 2.6$ Hz, 1H), 4.13 – 4.00 (m, 1H), 3.83 (s, 3H), 3.34 (dd, $J = 17.3, 10.9$ Hz, 1H), 3.23 (dd, $J = 17.0, 3.7$ Hz, 1H), 3.10 (dd, $J = 17.2, 9.4$ Hz, 1H), 3.04 (dd, $J = 16.8, 8.1$ Hz, 1H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.6, 157.1, 145.0, 131.2, 131.1, 129.7, 129.7, 128.6, 119.6, 117.1, 116.4, 111.6, 57.5, 55.4, 39.4, 24.5, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{NaO}_3\text{S}$ 392.1039, found 392.1035.

2-(3-(3-bromophenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2e)




White solid (65.4 mg, 78%); ^1H NMR (400 MHz, CDCl_3) δ 7.85 – 7.76 (m, 3H), 7.56 (d, J = 7.9 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.30 – 7.24 (m, 1H), 4.19 – 4.06 (m, 1H), 3.36 (dd, J = 17.3, 10.9 Hz, 1H), 3.24 (dd, J = 16.9, 3.7 Hz, 1H), 3.15 – 3.01 (m, 2H), 2.42 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 155.7, 145.2, 133.9, 131.9, 131.1, 130.3, 129.9, 129.7, 128.6, 125.4, 122.9, 116.2, 57.6, 39.2, 24.5, 21.7; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{BrN}_3\text{NaO}_2\text{S}$ 440.0039, found 440.0031.

2-(3-(4-methoxyphenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2f)



White solid (58.5 mg, 79%); ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, J = 7.9 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 4.10 – 3.96 (m, 1H), 3.82 (s, 3H), 3.31 (dd, J = 17.2, 10.8 Hz, 1H), 3.21 (dd, J = 17.0, 3.7 Hz, 1H), 3.07 (dd, J = 17.3, 9.0 Hz, 1H), 3.03 (dd, J = 17.0, 8.3 Hz, 1H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.7, 157.0, 144.8, 131.0, 129.7, 128.62, 128.55, 122.4, 116.5, 114.0, 57.3, 55.3, 39.3, 24.4, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{NaO}_3\text{S}$ 392.1039, found 392.1047.


2-(3-(*p*-tolyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2g)



White solid (59.2 mg, 84%); ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, J = 7.9 Hz, 2H), 7.54 (d, J = 7.8 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 7.8 Hz, 2H), 4.14 –


4.00 (m, 1H), 3.34 (dd, $J = 17.3, 10.8$ Hz, 1H), 3.24 (dd, $J = 17.0, 3.7$ Hz, 1H), 3.09 (dd, $J = 17.3, 9.6$ Hz, 1H), 3.01 (dd, $J = 17.0, 8.5$ Hz, 1H), 2.39 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.2, 144.9, 141.5, 131.3, 129.7, 129.4, 128.7, 127.2, 126.9, 116.4, 57.5, 39.5, 24.5, 21.6, 21.5; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{NaO}_2\text{S}$ 376.1090, found 376.1098.

2-(3-(4-chlorophenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2h)




White solid (48.1 mg, 64%); ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, $J = 8.1$ Hz, 2H), 7.57 (d, $J = 8.6$ Hz, 2H), 7.35 (d, $J = 8.6$ Hz, 2H), 7.31 (d, $J = 8.1$ Hz, 2H), 4.16 – 4.04 (m, 1H), 3.34 (dd, $J = 17.3, 10.9$ Hz, 1H), 3.22 (dd, $J = 17.0, 3.6$ Hz, 1H), 3.10 (dd, $J = 12.8, 8.8$ Hz, 1H), 3.06 (dd, $J = 12.5, 8.8$ Hz, 1H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.1, 145.1, 137.1, 131.1, 129.8, 129.0, 128.6, 128.4, 128.1, 116.3, 57.6, 39.2, 24.4, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{ClN}_3\text{NaO}_2\text{S}$ 396.0544, found 396.0542.

2-(3-(4-bromophenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2i)




White solid (56.3 mg, 67%); ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, $J = 8.0$ Hz, 2H), 7.56 – 7.47 (m, 4H), 7.32 (d, $J = 7.9$ Hz, 2H), 4.19 – 4.05 (m, 1H), 3.35 (dd, $J = 17.3, 10.9$ Hz, 1H), 3.23 (dd, $J = 17.0, 3.6$ Hz, 1H), 3.09 (dd, $J = 19.1, 8.5$ Hz, 1H), 3.05 (dd, $J = 17.4, 7.9$ Hz, 1H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.1, 145.1, 132.0, 131.3, 129.8, 128.9, 128.7, 128.3, 125.6, 116.2, 57.7, 39.2, 24.5, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{BrN}_3\text{NaO}_2\text{S}$ 440.0039, found 440.0047.

2-(1-tosyl-3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2j)




White solid (65.8 mg, 81%); ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.63 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.22 – 4.08 (m, 1H), 3.40 (dd, J = 17.3, 11.0 Hz, 1H), 3.24 (dd, J = 17.0, 3.6 Hz, 1H), 3.15 (dd, J = 21.0, 8.8 Hz, 1H), 3.10 (dd, J = 20.5, 8.8 Hz, 1H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 155.7, 145.2, 133.3 (q, J = 0.9 Hz), 132.5 (q, J = 32.6 Hz), 131.2, 129.8, 128.6, 127.2, 125.7 (q, J = 3.7 Hz), 123.6 (q, J = 272.4 Hz), 116.2, 57.8, 39.1, 24.5, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{16}\text{F}_3\text{N}_3\text{NaO}_2\text{S}$ 430.0808, found 430.0800.

2-(3-(4-fluorophenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2k)




White solid (50.8 mg, 71%); ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, J = 8.0 Hz, 2H), 7.64 (dd, J = 8.5, 5.3 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 7.07 (t, J = 8.4 Hz, 2H), 4.17 – 4.02 (m, 1H), 3.35 (dd, J = 17.3, 10.9 Hz, 1H), 3.22 (dd, J = 17.0, 3.6 Hz, 1H), 3.11 (dd, J = 16.6, 9.0 Hz, 1H), 3.07 (dd, J = 16.6, 8.3 Hz, 1H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2 (d, J = 252.5 Hz), 156.2, 145.0, 131.1, 129.8, 129.0 (d, J = 8.7 Hz), 128.6, 126.2 (d, J = 3.3 Hz), 116.3, 115.9 (d, J = 22.1 Hz), 57.5, 39.3, 24.4, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{FN}_3\text{NaO}_2\text{S}$ 380.0839, found 380.0835.

2-(3-(3,4-dichlorophenyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2l)




White solid (50.5 mg, 62%); ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, $J = 8.0$ Hz, 2H), 7.71 (s, 1H), 7.46 (s, 2H), 7.33 (d, $J = 7.9$ Hz, 2H), 4.20 – 4.05 (m, 1H), 3.34 (dd, $J = 17.4, 11.1$ Hz, 1H), 3.22 (d, $J = 16.8$ Hz, 1H), 3.15 – 3.02 (m, 2H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 155.0, 145.2, 135.2, 133.2, 131.1, 130.8, 129.9, 129.8, 128.6, 128.5, 125.9, 116.2, 57.7, 39.1, 24.5, 21.7; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{15}\text{Cl}_2\text{N}_3\text{NaO}_2\text{S}$ 430.0154, found 430.0150.

2-(3-(naphthalen-2-yl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2m)




White solid (49.7 mg, 64%); ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, $J = 8.6$ Hz, 1H), 7.88 – 7.78 (m, 6H), 7.57 – 7.49 (m, 2H), 7.31 (d, $J = 8.0$ Hz, 2H), 4.20 – 4.07 (m, 1H), 3.50 (dd, $J = 17.1, 10.3$ Hz, 1H), 3.34 – 3.18 (m, 2H), 3.07 (dd, $J = 17.0, 8.3$ Hz, 1H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.2, 145.0, 134.3, 132.6, 131.1, 129.7, 128.7, 128.6, 128.5, 127.8, 127.7, 127.6, 127.5, 126.9, 123.2, 116.5, 57.6, 39.3, 24.5, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{22}\text{H}_{19}\text{N}_3\text{NaO}_2\text{S}$ 412.1090, found 412.1098.

2-(3-(thiophen-2-yl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2n)




White solid (49.8 mg, 72%); ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, J = 8.3 Hz, 2H), 7.45 (dd, J = 5.1, 1.2 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 7.18 (dd, J = 3.7, 1.2 Hz, 1H), 7.04 (dd, J = 5.1, 3.7 Hz, 1H), 4.11 – 4.01 (m, 1H), 3.34 (dd, J = 17.1, 10.8 Hz, 1H), 3.23 (dd, J = 17.0, 3.7 Hz, 1H), 3.13 (dd, J = 17.1, 9.5 Hz, 1H), 3.02 (dd, J = 17.0, 8.4 Hz, 1H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.7, 145.0, 133.3, 131.0, 130.0, 129.7, 129.6, 128.8, 127.6, 116.3, 57.6, 40.1, 24.4, 21.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{NaO}_2\text{S}_2$ 368.0498, found 368.0489.

2-(3-(furan-2-yl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2o)



White solid (40.1 mg, 61%); ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, J = 8.1 Hz, 2H), 7.51 (d, J = 1.7 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 6.83 (d, J = 3.5 Hz, 1H), 6.49 (dd, J = 3.7, 1.7 Hz, 1H), 4.11 – 4.01 (m, 1H), 3.33 (dd, J = 17.4, 10.9 Hz, 1H), 3.22 (dd, J = 17.0, 3.3 Hz, 1H), 3.09 (dd, J = 17.5, 9.5 Hz, 1H), 3.01 (dd, J = 17.0, 8.3 Hz, 1H), 2.42 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.7, 145.6, 145.1, 145.0, 131.2, 129.8, 128.7, 116.2, 113.2, 112.1, 57.0, 39.3, 24.4, 21.7; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{NaO}_3\text{S}$ 352.0726, found 352.0721.


2-(3-isopropyl-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2p)



White solid (47.4 mg, 78%); ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 3.94 – 3.81 (m, 1H), 3.08 (dd, J = 17.0, 3.7 Hz, 1H), 2.92 (dd, J = 17.0, 7.9 Hz, 1H), 2.84 (dd, J = 17.6, 10.6 Hz, 1H), 2.68 (dd, J = 17.6, 9.2 Hz, 1H), 2.63 – 2.53 (m, 1H), 2.43 (s, 3H), 1.06 (d, J = 3.7 Hz, 3H), 1.04 (d, J = 3.6 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.1, 144.7, 131.0, 129.5, 128.8, 116.3, 56.8,


39.4, 29.7, 24.5, 21.6, 19.8, 19.5; HRMS (ESI-TOF) m/z : $[M+Na]^+$ calcd for $C_{15}H_{19}N_3NaO_2S$ 328.1090, found 328.1093.

2-(3-cyclohexyl-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2q)




Colorless oil (51.8 mg, 75%); 1H NMR (400 MHz, $CDCl_3$) δ 7.72 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 3.89 – 3.78 (m, 1H), 3.08 (dd, J = 17.0, 3.7 Hz, 1H), 2.91 (dd, J = 16.9, 8.0 Hz, 1H), 2.83 (dd, J = 17.6, 10.7 Hz, 1H), 2.67 (dd, J = 17.6, 9.1 Hz, 1H), 2.43 (s, 3H), 2.33 – 2.21 (m, 1H), 1.74 – 1.60 (m, 5H), 1.33 – 1.10 (m, 5H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 166.4, 144.8, 130.7, 129.5, 128.7, 116.4, 56.5, 39.8, 39.0, 30.1, 29.8, 25.6, 25.5, 25.4, 24.5, 21.6; HRMS (ESI-TOF) m/z : $[M+Na]^+$ calcd for $C_{18}H_{23}N_3NaO_2S$ 368.1403, found 368.1409.

2-(3-(tert-butyl)-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2r)




Colorless oil (58.1 mg, 91%); 1H NMR (400 MHz, $CDCl_3$) δ 7.71 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 3.90 – 3.77 (m, 1H), 3.06 (dd, J = 16.9, 3.7 Hz, 1H), 2.92 (dd, J = 15.3, 6.0 Hz, 1H), 2.86 (dd, J = 15.9, 8.9 Hz, 1H), 2.67 (dd, J = 17.6, 9.2 Hz, 1H), 2.42 (s, 3H), 1.06 (s, 9H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 169.9, 144.8, 130.5, 129.4, 128.7, 116.4, 57.2, 38.4, 34.2, 27.7, 24.5, 21.6; HRMS (ESI-TOF) m/z : $[M+Na]^+$ calcd for $C_{16}H_{21}N_3NaO_2S$ 342.1247, found 342.1241.

2-(4,4-dimethyl-3-phenyl-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2s)




White solid (42.7 mg, 58%); ^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, J = 8.2 Hz, 2H), 7.61 – 7.54 (m, 2H), 7.47 – 7.32 (m, 5H), 3.55 (dd, J = 17.2, 3.7 Hz, 1H), 3.40 (dd, J = 10.5, 3.7 Hz, 1H), 2.92 (dd, J = 17.2, 10.5 Hz, 1H), 2.44 (s, 3H), 1.43 (s, 3H), 1.29 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.6, 145.1, 130.3, 129.73, 129.65, 129.0, 128.6, 127.6, 116.5, 67.3, 51.7, 26.1, 21.7, 19.5, 18.1; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{20}\text{H}_{21}\text{N}_3\text{NaO}_2\text{S}$ 390.1247, found 390.1252.

3-phenyl-1-tosyl-3a,4,5,6,7,7a-hexahydro-1H-indazole-7-carbonitrile (2t)




White solid (53.7 mg, 71%); ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, J = 8.3 Hz, 2H), 7.72 – 7.65 (m, 2H), 7.46 – 7.36 (m, 3H), 7.32 (d, J = 8.0 Hz, 2H), 4.31 – 4.24 (m, 1H), 3.46 – 3.33 (m, 2H), 2.39 (s, 3H), 2.09 – 1.99 (m, 3H), 1.84 – 1.68 (m, 2H), 1.36 – 1.27 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.2, 145.1, 131.0, 129.69, 129.59, 129.1, 128.8, 127.1, 120.2, 62.9, 42.6, 27.7, 26.1, 22.9, 21.6, 18.9; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{21}\text{H}_{21}\text{N}_3\text{NaO}_2\text{S}$ 402.1247, found 402.1239.

2-(1-acetyl-4,4-dimethyl-3-phenyl-4,5-dihydro-1H-pyrazol-5-yl)acetonitrile (2u)




White solid (28.5 mg, 56%); ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, $J = 7.5$ Hz, 2H), 7.48 – 7.38 (m, 3H), 4.34 (dd, $J = 7.2, 2.6$ Hz, 1H), 3.04 (dd, $J = 17.1, 7.1$ Hz, 1H), 2.79 (dd, $J = 17.1, 2.6$ Hz, 1H), 2.40 (s, 3H), 1.51 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.2, 162.1, 130.3, 130.1, 128.7, 127.6, 117.0, 64.2, 50.0, 28.1, 21.7, 19.0, 16.8; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}$ 278.1264, found 278.1270.

2-(6-phenyl-2-tosyl-2,3,4,5-tetrahydropyridazin-3-yl)acetonitrile (2v)



White solid (28.4 mg, 40%); ^1H NMR (400 MHz, CDCl_3) δ 7.87 (d, $J = 8.3$ Hz, 2H), 7.69 (dd, $J = 6.7, 2.9$ Hz, 2H), 7.42 – 7.35 (m, 3H), 7.32 (d, $J = 8.1$ Hz, 2H), 4.75 – 4.65 (m, 1H), 2.88 (dd, $J = 16.9, 4.5$ Hz, 1H), 2.79 – 2.67 (m, 1H), 2.56 (dd, $J = 16.9, 10.5$ Hz, 1H), 2.51 – 2.31 (m, 5H), 1.88 – 1.75 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.1, 144.5, 136.1, 134.9, 129.7, 129.7, 128.5, 128.0, 125.3, 116.3, 47.4, 21.6, 20.63, 20.60, 17.6; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{NaO}_2\text{S}$ 376.1090, found 376.1098.

2,2,6,6-tetramethyl-1-((3-phenyl-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)methoxy)peridine (3)



White solid (72.9 mg, 78%); ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, $J = 8.0$ Hz, 2H), 7.73 – 7.66 (m, 2H), 7.44 – 7.35 (m, 3H), 7.27 (d, $J = 7.8$ Hz, 2H), 4.31 (dd, $J = 9.2, 3.8$ Hz, 1H), 4.12 (dd, $J = 9.2, 7.3$ Hz, 1H), 4.01 – 3.88 (m, 1H), 3.18 (dd, $J = 17.2, 8.9$ Hz, 1H), 3.10 (dd, $J = 17.2, 11.0$ Hz, 1H), 2.38 (s, 3H), 1.58 – 1.29 (m, 6H), 1.23 (s, 6H), 1.07 (d, $J = 8.7$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.3, 144.1, 131.9,

130.8, 130.5, 129.4, 128.51, 128.50, 126.9, 77.9, 60.0, 59.8, 39.5, 37.3, 33.2, 33.0, 21.5, 20.0, 17.0; HRMS (ESI-TOF) m/z : $[M+Na]^+$ calcd for $C_{26}H_{35}N_3NaO_3S$ 492.2291, found 492.2285.

S. Chen, W. Chen, X. Chen, G. Chen, L. Ackermann and X. Tian, Copper (I)-catalyzed oxyamination of β,γ -unsaturated hydrazones: synthesis of dihydropyrazoles, *Org. Lett.*, 2019, **21**, 7787-7790.

References

- (1) T. Imai and S. Nishida, A mild and convenient Barbier-type allylation of aldehydes to homoallylic alcohols via iodide ion promoted stannylation of allylic bromides and chlorides with tin(II) chloride, *Synthesis*, 1993, 395–399.
- (2) S. Rajam, A.V. Jadhav, Q. Li, S. K. Sarkar, P. N. D. Singh, A. Rohr, T. C. S. Pace, R. Li, J. A. Krause, C. Bohne, B. S. Ault and A. D. Gudmundsdottir, Triplet sensitized photolysis of a vinyl azide: Direct detection of a triplet vinyl azide and nitrene, *J. Org. Chem.*, 2014, **79**, 9325–9334.
- (3) Q. Wei, J.-R. Chen, X.-Q. Hu, X.-C. Yang, B. Lu and W.-J. Xiao, Photocatalytic radical trifluoromethylation/cyclization cascade: synthesis of CF₃-containing pyrazolines and isoxazolines, *Org. Lett.*, 2015, **17**, 4464–4467.
- (4) S. Kobayashi and K. Nishio, Facile synthesis of both *syn* and *anti* homoallylic alcohols from allyl chlorides via organosilicon intermediates, *Chem. Lett.*, 1994, **23**, 1773–1776.
- (5) M. Chen, L.-J. Wang, P.-X. Ren, X.-Y. Hou, Z. Fang, M.-N. Han and W. Li, Copper-catalyzed diamination of alkenes of unsaturated ketohydrazones with amines, *Org. Lett.*, 2018, **20**, 510–513.
- (6) Z. Zou, W. Zhang, Y. Wang, L. Kong, G. Karotsis, Y. Wang and Y. Pan, Electrochemically promoted fluoroalkylation–distal functionalization of unactivated alkenes, *Org. Lett.*, 2019, **21**, 1857–1862.

